Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-3608
Abstract: Purpose: Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of resistance to type I and type II MET TKIs and their impact… read more here.
Keywords: molecular mechanisms; met exon; resistance met; mechanisms resistance ... See more keywords
miR‐205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling
Sign Up to like & getrecommendations! Published in 2018 at "EMBO Molecular Medicine"
DOI: 10.15252/emmm.201708746
Abstract: The onset of secondary resistance represents a major limitation to long‐term efficacy of target therapies in cancer patients. Thus, the identification of mechanisms mediating secondary resistance is the key to the rational design of therapeutic… read more here.
Keywords: errfi1; resistance met; mir 205; inhibition ... See more keywords
Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1024818
Abstract: Background Non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping (METex14) occurs in 3-4% of NSCLC cases and defines a subset of patients with distinct characteristics. While MET targeted therapy has led to… read more here.
Keywords: lung cancer; resistance met; analysis; resistance ... See more keywords